Reviewing Atossa Genetics (NASDAQ:ATOS) and QHSLab (OTCMKTS:USAQ)

QHSLab (OTCMKTS:USAQ) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares QHSLab and Atossa Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QHSLab	15.60%	-27.74%	-6.98%
Atossa Genetics	N/A	-84.91%	-72.36%

Earnings & Valuation

This table compares QHSLab and Atossa Genetics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QHSLab	$2.69 million	1.46	$460,000.00	$0.03	11.60
Atossa Genetics	N/A	N/A	-$34.77 million	($3.21)	-0.74

QHSLab has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than QHSLab, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for QHSLab and Atossa Genetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QHSLab	0	0	0	0	0.00
Atossa Genetics	2	0	3	0	2.20

Atossa Genetics has a consensus target price of $20.33, suggesting a potential upside of 761.58%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than QHSLab.

Volatility and Risk

QHSLab has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Institutional & Insider Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. 74.2% of QHSLab shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

QHSLab beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.